<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05114772</url>
  </required_header>
  <id_info>
    <org_study_id>34816/7/19</org_study_id>
    <nct_id>NCT05114772</nct_id>
  </id_info>
  <brief_title>Pre Procedural Biomarkers Might Predict Recurrent Atrial Fibrillation After Catheter Ablation</brief_title>
  <official_title>Pre Procedural High Serum Visfatin and Tumor Necrosis Factors &quot;Alpha&quot; Might Predict Recurrent Atrial Fibrillation After Catheter Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the predictive value of serum levels of adipocytokines and primary phase&#xD;
      reactant for recurrent atrial fibrillation (RAF) after catheter ablation in 26 patients had&#xD;
      persistent and 91 patients had paroxysmal AF. During 12-m follow-up, 41 patients had RAF&#xD;
      (35%). Patients had RAF were significantly older, had significantly higher BMI, lower&#xD;
      ejection fraction and wider maximal left atrial diameter (LAD). Serum hs-CRP, IL-6, TNF-α,&#xD;
      visfatin, and adiponectin levels were significantly higher in patients developed. Elevated&#xD;
      serum levels of TNF-α, visfatin and adiponectin are a significant positive predictors for&#xD;
      RAF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: Estimation of serum levels of visfatin, adiponectin, tumor necrosis factor-α&#xD;
      (TNF-α), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) in patients&#xD;
      had atrial fibrillation (AF) resistant to medical treatment and assigned to catheter ablation&#xD;
      (CA) to evaluate these biomarkers as predictors for recurrent AF (RAF).&#xD;
&#xD;
      Patients &amp; Methods: 117 patients; 26 patients had persistent and 91 patients had paroxysmal&#xD;
      AF underwent had clinical and echographic evaluations and gave blood samples for ELISA&#xD;
      estimation of serum levels of studied cytokines. CA was performed through isolation of all&#xD;
      pulmonary veins according to the stepwise procedure of ablation. Patients were re-evaluated&#xD;
      every three months till 12-m follow-up for post-procedural RAF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent Atrial Fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>Recurrent Atrial Fibrillation after Catheter ablation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Recurrent Atrial fibrillation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients developed Recurrent Atrial fibrillation catheter ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO Recurrent Atrial fibrillation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients didn't develop Recurrent Atrial fibrillation catheter ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Measuring Serum bio-markers</intervention_name>
    <description>ELISA Estimation of Serum visfatin and tumor necrosis factor-alpha</description>
    <arm_group_label>NO Recurrent Atrial fibrillation</arm_group_label>
    <arm_group_label>Recurrent Atrial fibrillation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic paroxysmal or persistent AF that was resistant to medical acceptable daily&#xD;
             dose therapy in patients who were free of exclusion criteria and accepted to sign the&#xD;
             written fully informed consent to undergo CA and to give pre-procedural blood samples.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of the presence of longstanding persistent or permanent AF,&#xD;
&#xD;
          -  myocardial infarction, acute coronary syndrome (ACS),&#xD;
&#xD;
          -  significant heart failure (NYHA3),&#xD;
&#xD;
          -  dilated or hypertrophic cardiomyopathy,&#xD;
&#xD;
          -  left ventricular ejection fraction (LVEF)&lt; 35%, congenital pathologies,&#xD;
&#xD;
          -  significant valvular heart disease,&#xD;
&#xD;
          -  pulmonary embolism,&#xD;
&#xD;
          -  venous thrombosis,&#xD;
&#xD;
          -  intracardiac thrombus or inability to take warfarin or other oral anticoagulants,&#xD;
&#xD;
          -  hepatic or renal insufficiency,&#xD;
&#xD;
          -  acute inflammatory states (sepsis, chronic obstructive pulmonary disease in acute&#xD;
             phase),&#xD;
&#xD;
          -  cancer,&#xD;
&#xD;
          -  autoimmune pathologies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amr El kassas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of medicine Tanta university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tanta university</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Amr Fayez Al-kassas</investigator_full_name>
    <investigator_title>lecturer of Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

